Records containing: Neuroendocrine Tumors
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-06A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)
-
CLINICAL_TRIALS study record update · 2026-04-01CaboLife: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour
-
CLINICAL_TRIALS study record update · 2026-03-30Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
-
CLINICAL_TRIALS study record update · 2026-03-27A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
-
CLINICAL_TRIALS study record update · 2026-03-24Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an NEM1 Mutation: the Progastrin-NEM1 Study
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-03-23Combined 68Ga-DOTATATE and 18F-FDG PET/CT Imaging in Patients With Well-differentiated, G2-G3, Gastroenteropancreatic (GEP)-Neuroendocrine Tumors (NETs) - A Pilot Study
-
CLINICAL_TRIALS study record update · 2026-03-20Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine
-
CLINICAL_TRIALS study record update · 2026-03-19Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate
-
CLINICAL_TRIALS study record update · 2026-03-18Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring
-
CLINICAL_TRIALS study record update · 2026-03-17A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2026-03-17Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-03-10A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-03-10A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
-
CLINICAL_TRIALS study record update · 2026-03-09Definition of PET REsponSe CrItEria for Neuroendocrine Tumors (PRESCIENT)
-
CLINICAL_TRIALS study record update · 2026-03-06An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
-
CLINICAL_TRIALS study record update · 2026-03-06Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
-
CLINICAL_TRIALS study record update · 2026-03-04Carcinoid Heart Disease National Registry of Poland
-
CLINICAL_TRIALS study record update · 2026-03-02A Phase 2 Single-Arm Multicenter Study of Entinostat in Patients With Relapsed or Refractory Abdominal Neuroendocrine (NE) Tumors
-
CLINICAL_TRIALS study record update · 2026-02-27Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers
-
CLINICAL_TRIALS study record update · 2026-02-18Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
-
CLINICAL_TRIALS study record update · 2026-02-13Epidemiological Study of the Therapeutic Management of Well-differentiated Grade 3 (WHO Classification) Neuroendocrine Digestive Tumors From the Prospective Data of the French Neuroendocrine Tumors Registry (GTE)
-
CLINICAL_TRIALS study record update · 2026-02-12Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
-
CLINICAL_TRIALS study record update · 2026-02-11Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors: Assessment of Safety and Efficacy
-
CLINICAL_TRIALS study record update · 2026-02-10The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers
-
CLINICAL_TRIALS study record update · 2026-02-0918F-DOPA II - PET Imaging Optimization